Maternal omega-3 fatty acid supplementation on vitamin B12 rich diet improves brain omega-3 fatty acids, neurotrophins and cognition in the Wistar rat offspring

2014 ◽  
Vol 36 (10) ◽  
pp. 853-863 ◽  
Author(s):  
Richa Rathod ◽  
Amrita Khaire ◽  
Nisha Kemse ◽  
Anvita Kale ◽  
Sadhana Joshi
Keyword(s):  
Fatty Acids ◽  
Fatty Acid ◽  
Vitamin B12 ◽  
Wistar Rat ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Fatty Acid Supplementation ◽  
Acid Supplementation ◽  
Omega 3 Fatty Acid ◽  
Rat Offspring

scholarly journals Omega-3 fatty acid supplementation is associated with favorable outcomes in patients with sepsis: an updated meta-analysis

2020 ◽  
Vol 48 (12) ◽  
pp. 030006052095368
Author(s):  
Chenyang Wang ◽  
Dong Han ◽  
Xiaojing Feng ◽  
Jing Wu
Keyword(s):  
Fatty Acids ◽  
Fatty Acid ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Gastrointestinal Dysfunction ◽  
Fatty Acid Supplementation ◽  
Acid Supplementation ◽  
Omega 3 Fatty Acid

Objectives The efficacy of omega-3 fatty acids in the treatment of sepsis is controversial. We conducted an updated meta-analysis to clarify the efficacy of omega-3 fatty acids in patients with sepsis. Methods PubMed, EMBASE, and the Cochrane Library were searched for randomized clinical trials (RCTs) on omega-3 fatty acid supplementation in adults with sepsis. Results Twenty eligible RCTs involving 1514 patients were included in the meta-analysis. Omega-3 fatty acid supplementation was linked to reductions of mortality ( I2 = 0, relative risk [RR] = 0.82, 95% confidence interval [CI] = 0.69–0.97), the duration of mechanical ventilation (DMV; I2 = 74%, weighted mean difference [WMD] = −2.20, 95% CI = −4.00 to −0.40), and intensive care unit (ICU) length of stay (LOS; I2 = 91%, WMD = −3.86, 95% CI = −5.72 to −2.01). Subgroup analysis illustrated that mortality was significantly reduced in patients with sepsis and gastrointestinal dysfunction (RR = 0.5, 95% CI = 0.29–0.86, I2 = 0). Conclusion Omega-3 fatty acid supplementation might be associated with reduced mortality in patients with sepsis, especially those with gastrointestinal dysfunction. Furthermore, omega-3 fatty acid administration could shorten DMV and ICU LOS.

Review of Omega-3 Fatty Acids for the Treatment of Attention Deficit/Hyperactivity Disorder

2009 ◽  
Vol 2 ◽  
pp. HSI.S3614
Author(s):  
Jamie N. Brown ◽  
Nicole Panosh
Keyword(s):  
Fatty Acids ◽  
Fatty Acid ◽  
Attention Deficit ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Fatty Acid Supplementation ◽  
Acid Supplementation ◽  
Omega 3 Fatty Acid ◽  
Hyperactivity Disorder ◽  
Clinically Significant

Objective To review the efficacy of omega-3 fatty acids in the treatment of attention deficit/hyperactivity disorder (ADHD). Data Souces Literature was accessed via MEDLINE (1950–February 2009) and International Pharmaceutical Abstracts (1960–2009) using the medical subject heading terms omega-3 fatty acids and attention deficit disorder with hyperactivity. Additional references were found by searching bibliographic references of resulting citations. Study Selection and Data Extraction All English-language, placebo controlled publications identified were analyzed for significance. Studies relevant to the objective were used, including eight studies evaluating the use of omega-3 fatty acid in the treatment of children with symptoms of ADHD. Data Synthesis Omega-3 fatty acid supplementation has been found to have variable efficacy in the treatment of patients with ADHD. Of the eight studies evaluated, three demonstrated no significant improvements in any evaluation criteria, with five studies reporting positive effects in at least one outcome measure. All positive efficacy studies included concomitant supplementation with omega-6 fatty acids. No clinically significant adverse effects were identified in the reviewed studies. Conclusions Based on the available data, current fatty acid supplementation techniques do not appear to be a consistant method of controlling ADHD symptoms. Without better evidence to determine the true value of fatty acids in the treatment of ADHD, omega-3 fatty acid use should be isolated to adjuvant supplementation or used in patients unable or unwilling to take stimulant medications. If recommended, there does not appear to be clinically significant adverse events associated with omega-3 fatty acid supplementation and this would be a safe treatment modality.

The effect of Omega-3 fatty acid supplementation in systemic lupus erythematosus patients: A systematic review

Lupus ◽  
2022 ◽  
pp. 096120332110679
Author(s):  
Nina Ramessar ◽  
Abhilasha Borad ◽  
Naomi Schlesinger
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Fatty Acids ◽  
Fatty Acid ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Omega 3 ◽  
Systemic Lupus ◽  
Fatty Acid Supplementation ◽  
Acid Supplementation ◽  
Omega 3 Fatty Acid

Objective Many rheumatologists are inundated with questions about what “natural remedies” and “anti-autoimmune diets” exist for decreasing Systemic Lupus Erythematosus (SLE) disease activity. Over the last three decades, there has been an abundance of data from several different trials about omega-3 fatty acids sourced from fish oil, but the findings have been contradictory. This review seeks to present this data so that evidence-based recommendations can be given to patients, supporting the use of an adjuvant regimen with their present immunosuppression. Methods A literature search was conducted using the PubMed, Google Scholar, MEDLINE, and Scopus electronic databases to retrieve relevant articles for this review. Trials conducted on human subjects with SLE with full publications in English were included from 1 January 1980 to 1 April 2021. The impact of fish oil-derived omega-3 fatty acid supplementation on specific clinical features, the innate and adaptive immune response, biomarkers, and disease activity measures were assessed. The initial search yielded 7519 articles, but only 13 met our criteria and were eligible for this review. Results Data from thirteen articles were assessed. Ten trials assessed disease activity as an outcome, with eight trials demonstrating an improvement in patients in the omega-3 fatty acid group as assessed by a validated clinical tool or individual patient criteria. There was a significant improvement in Systemic Lupus Activity Measure-Revised (SLAM-R) scores at week 12 ( p = .009) and week 24 ( p < .001). Additionally, a reduction of urinary 8-isoprostane, a non-invasive marker of disease activity, was observed. There was no treatment benefit seen with respect to renal parameters such as serum creatinine or 24-hour urine protein; or systemic parameters such as C3, C4, or anti-double stranded DNA (anti-dsDNA) levels regardless of the dose of the omega-3 LUPUS fatty acids or duration of the trial. Conclusion While there is conflicting evidence about the benefits of omega-3 fatty acid supplementation on SLE disease activity, specific measures have demonstrated benefits. Current data show that there is a potential benefit on disease activity as demonstrated by SLAM-R, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and British Isles Lupus Assessment Group (BILAG) scores and plasma membrane arachidonic acid composition and urinary 8-isoprostane levels, with minimal adverse events.

Preconceptional omega-3 fatty acid supplementation on a micronutrient-deficient diet improves the reproductive cycle in Wistar rats

2013 ◽  
Vol 25 (7) ◽  
pp. 1085 ◽  
Author(s):  
Akshaya P. Meher ◽  
Asmita A. Joshi ◽  
Sadhana R. Joshi
Keyword(s):  
Folic Acid ◽  
Fatty Acid ◽  
Vitamin B12 ◽  
Mammary Glands ◽  
Oestrous Cycle ◽  
Omega 3 ◽  
Fatty Acid Supplementation ◽  
Acid Supplementation ◽  
Omega 3 Fatty Acid ◽  
Group A

Folic acid and vitamin B12 deficiencies are associated with high reproductive risks ranging from infertility to fetal structural defects. The aim of the present study was to examine the effects of preconceptional omega-3 fatty acid supplementation (eicosapentaenoic acid and docosahexaenoic acid) to a micronutrient-deficient diet on the reproductive cycle in Wistar rats. Female rats were divided into five groups from birth and throughout pregnancy: a control group, a folic acid-deficient (FD) group, a vitamin B12-deficient (BD) group, a folic acid-deficient + omega-3 fatty acid-supplemented (FDO) group and a vitamin B12 deficient + omega-3 fatty acid-supplemented (BDO) group. Dams were killed on gestation Day 20 and their ovaries and mammary glands were dissected out and subjected to histological examination. Maternal micronutrient deficiency (FD and BD groups) resulted in an abnormal oestrous cycle (P < 0.001), whereas omega-3 fatty acid supplementation (FDO and BDO groups) restored the oestrous cycle to normal. There were fewer corpora lutea in the ovaries of FD rats compared with controls. In addition, rats in both the FD and BD groups exhibited an absence of lactating ducts in their mammary glands compared with controls. The findings of the present study indicate, for the first time, that maternal micronutrient deficiency affects the oestrous cycle and morphology of the ovary and mammary glands. Omega-3 fatty acid supplementation ameliorated these effects. This may have implications for infertility and pregnancy outcomes.

Effect of vitamin B12 and omega-3 fatty acid supplementation on brain neurotrophins and cognition in rats: A multigeneration study

Biochimie ◽  
2016 ◽  
Vol 128-129 ◽  
pp. 201-208 ◽  
Author(s):  
Richa S. Rathod ◽  
Amrita A. Khaire ◽  
Anvita A. Kale ◽  
Sadhana R. Joshi
Keyword(s):  
Fatty Acid ◽  
Vitamin B12 ◽  
Omega 3 ◽  
Fatty Acid Supplementation ◽  
Acid Supplementation ◽  
Omega 3 Fatty Acid

One month of omega-3 fatty acid supplementation improves lipid profiles, glucose levels and blood pressure in overweight schoolchildren with metabolic syndrome

2016 ◽  
Vol 29 (10) ◽  
Author(s):  
Salvador García-López ◽  
Rosina E. Villanueva Arriaga ◽  
Oralia Nájera Medina ◽  
Carmen Paulina Rodríguez López ◽  
Lauro Figueroa-Valverde ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Fatty Acids ◽  
Fatty Acid ◽  
Lipid Profiles ◽  
Omega 3 ◽  
Pufa Supplementation ◽  
Fatty Acid Supplementation ◽  
Acid Supplementation ◽  
Omega 3 Fatty Acid

AbstractBackground:This study sought to investigate the effects of omega (ω)-3 polyunsaturated fatty acid (PUFA) supplementation on the lipid profiles and glucose (GLU) levels of overweight (OW) schoolchildren with metabolic syndrome (MS).Methods:Thirty-nine OW schoolchildren with MS, including 19 girls and 20 boys, received 1-month of dietary supplementation with gel capsules containing ω-3 fatty acids. Fasting lipid profiles and GLU levels were measured before and after supplementation.Results:Both sexes of OW schoolchildren with MS who received daily supplementation with 2.4 g of ω-3 fatty acids for 1 month displayed improved lipid profiles, reduced fasting GLU levels and reduced blood pressure (BP).Conclusions:These findings support the addition of omega-3 fatty acid supplementation to programs aiming to improve the metabolic status of OW children with MS, although additional research on the longer-term safety and efficacy of this treatment in this population is required.

Sign in / Sign up

Export Citation Format

Share Document